JP7178108B2 - 血管造影において使用するためのデンドリマー組成物 - Google Patents

血管造影において使用するためのデンドリマー組成物 Download PDF

Info

Publication number
JP7178108B2
JP7178108B2 JP2019558350A JP2019558350A JP7178108B2 JP 7178108 B2 JP7178108 B2 JP 7178108B2 JP 2019558350 A JP2019558350 A JP 2019558350A JP 2019558350 A JP2019558350 A JP 2019558350A JP 7178108 B2 JP7178108 B2 JP 7178108B2
Authority
JP
Japan
Prior art keywords
dendrimer
composition
integer
subject
dendrimers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019558350A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020520393A5 (https=
JP2020520393A (ja
Inventor
カナン ランガラマヌジャム，
シバ プラモス カムバームパティ，
ジェラルド エー． ラッティー，
リシ シャルマ，
Original Assignee
ザ・ジョンズ・ホプキンス・ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ジョンズ・ホプキンス・ユニバーシティー filed Critical ザ・ジョンズ・ホプキンス・ユニバーシティー
Publication of JP2020520393A publication Critical patent/JP2020520393A/ja
Publication of JP2020520393A5 publication Critical patent/JP2020520393A5/ja
Application granted granted Critical
Publication of JP7178108B2 publication Critical patent/JP7178108B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/102—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for optical coherence tomography [OCT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
    • A61B3/1241—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes specially adapted for observation of ocular blood flow, e.g. by fluorescein angiography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0062—Arrangements for scanning
    • A61B5/0066—Optical coherence imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polyamides (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Eye Examination Apparatus (AREA)
JP2019558350A 2017-04-27 2018-04-27 血管造影において使用するためのデンドリマー組成物 Active JP7178108B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762490936P 2017-04-27 2017-04-27
US62/490,936 2017-04-27
PCT/US2018/029882 WO2018201007A2 (en) 2017-04-27 2018-04-27 Dendrimer compositions for use in angiography

Publications (3)

Publication Number Publication Date
JP2020520393A JP2020520393A (ja) 2020-07-09
JP2020520393A5 JP2020520393A5 (https=) 2021-05-27
JP7178108B2 true JP7178108B2 (ja) 2022-11-25

Family

ID=63919237

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019558350A Active JP7178108B2 (ja) 2017-04-27 2018-04-27 血管造影において使用するためのデンドリマー組成物

Country Status (8)

Country Link
US (1) US11160881B2 (https=)
EP (1) EP3615086A4 (https=)
JP (1) JP7178108B2 (https=)
CN (1) CN110913916A (https=)
AU (1) AU2018258654B2 (https=)
CA (1) CA3061630C (https=)
IL (1) IL270169B2 (https=)
WO (1) WO2018201007A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4364724T3 (da) 2018-05-10 2025-12-22 Regeneron Pharma Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
JP7759322B2 (ja) 2019-12-04 2025-10-23 アシュバッタ セラピューティクス， インコーポレイテッド 眼に薬物送達するためのデンドリマー組成物および方法
CN112023061B (zh) * 2020-07-30 2022-07-12 东华大学 一种功能化树状大分子包裹金纳米颗粒/PD-L1 siRNA复合物及其制备和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540664A (ja) 2007-10-05 2010-12-24 ウェイン ステート ユニバーシティー 合成物の持続的な放出のためのデンドリマー
US20130165771A1 (en) 2011-12-17 2013-06-27 Ming Ni Use of fitc-dextran as dye for fundus angiography and methods thereof
CN103804693A (zh) 2014-01-24 2014-05-21 中国科学院化学研究所 树枝状聚缩酮及其制备方法和应用
WO2014109927A1 (en) 2013-01-11 2014-07-17 The Regents Of The University Of Michigan Synthesis and isolation of dendrimer based imaging systems
JP2017514347A (ja) 2014-03-21 2017-06-01 サン パテント トラスト Ｄ２ｄ通信におけるスケジューリング要求手順

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2093165C1 (ru) 1993-07-06 1997-10-20 Линд Роберт Мейнгардтович Средство для лечения конъюнктивитов
AU6269799A (en) 1998-09-28 2000-04-17 Johns Hopkins University, The Adrenoleukodystrophy treatments and drug screening
US6312725B1 (en) 1999-04-16 2001-11-06 Cohesion Technologies, Inc. Rapid gelling biocompatible polymer composition
US20030180250A1 (en) 2002-03-22 2003-09-25 Council Of Scientific And Industrial Research Compositions and complexes containing a macromolecular compound as potential anti-inflammatory agents
AU2003301129A1 (en) 2002-12-20 2004-07-22 Control Delivery Systems, Inc. Steroid compositions for intraocular use
EP1689354A4 (en) 2003-11-20 2010-07-14 Othera Holding Inc REDUCTION OF CATARACTS, MACULAR GENERATION AND OTHER EYES DISEASES
US20050276917A1 (en) 2004-06-15 2005-12-15 Helene Bolm Process for the preparation of powder coatings
EP1676569A1 (en) 2004-12-30 2006-07-05 Pevion Biotech Ltd. Lyophilization of virosomes
MX2007010402A (es) 2005-04-20 2008-01-22 Dendritic Nanotechnologies Inc Polimeros dendriticos con amplificacion mejorada y funcionalidad interior.
US7674781B2 (en) 2006-04-28 2010-03-09 Heather Sheardown Hyaluronic acid-retaining polymers
MX2008014520A (es) 2006-05-22 2008-11-27 Elan Pharm Inc Preparacion de conjugados polimericos de compuestos terapeuticos, agricolas, y de aditivos para alimentos.
JP5659789B2 (ja) 2008-04-04 2015-01-28 コニカミノルタ株式会社 非水系インクジェットインク、非水系インクジェットインクの製造方法及びインクジェット記録方法
WO2009142754A1 (en) 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dendritic conjugates and methods of use
US20100015231A1 (en) 2008-07-17 2010-01-21 E.I. Du Pont De Nemours And Company Low swell, long-lived hydrogel sealant
US8821870B2 (en) 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
WO2010039861A2 (en) 2008-09-30 2010-04-08 The Regents Of The University Of Michigan Dendrimer conjugates
CA2767163A1 (en) 2009-06-15 2010-12-23 Wayne State University Dendrimer based nanodevices for therapeutic and imaging purposes
US20120177593A1 (en) 2009-07-20 2012-07-12 The Regents Of The University Of Michigan Synthesis of dendrimer conjugates
WO2011072290A2 (en) 2009-12-11 2011-06-16 The Regents Of The University Of Michigan Targeted dendrimer-drug conjugates
EP2552458A4 (en) 2010-03-31 2014-08-27 Univ Wayne State INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES
JP2013540748A (ja) 2010-09-16 2013-11-07 コーネル ユニバーシティー 血液脳関門の透過性を調節するためのアデノシン受容体シグナル伝達の使用法
WO2012142470A1 (en) 2011-04-13 2012-10-18 Massachusetts Institute Of Technology Biocompatible adhesive materials and methods
US20130123330A1 (en) 2011-07-15 2013-05-16 Patrick Y. Lu Dual Targeted siRNA Therapeutics for Treatment of Diabetic Retinopathy and Other Ocular Neovascularization Diseases
JP2015526434A (ja) 2012-08-14 2015-09-10 アンジオケム インコーポレーテッド ペプチド−デンドリマーコンジュゲート及びその使用
WO2014178892A1 (en) 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
US20160122406A1 (en) 2013-06-07 2016-05-05 The Administrators Of The Tulane Educational Fund Analogs of pituitary adenylate cyclase-activating polypeptide (pacap) and methods for their use
CN105813690A (zh) 2013-08-21 2016-07-27 协和大学 树状聚合物-白藜芦醇复合物
WO2015038493A1 (en) 2013-09-10 2015-03-19 The Research Foundation For The State University Of New York Synthesis of novel asymmetric bow-tie pamam dendrimer-based conjugates for tumor-targeting drug delivery
CA2946422C (en) * 2014-04-30 2019-03-05 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
CN103999853B (zh) 2014-06-11 2015-07-22 中国农业大学 荧光树枝状纳米大分子在制备药物载体中的应用
JP6342575B2 (ja) 2014-08-13 2018-06-13 ザ・ジョンズ・ホプキンス・ユニバーシティー 脳腫瘍への選択的デンドリマー送達
CN106659798A (zh) * 2014-08-13 2017-05-10 约翰霍普金斯大学 树枝状聚合物组合物和在治疗神经与cns病症中的用途
CA3003589C (en) 2015-10-29 2021-12-07 The Johns Hopkins University Dendrimer compositions and methods for treatment of peroxisomal disorders and leukodystrophies
CN108289872B (zh) 2015-10-29 2021-04-02 约翰霍普金斯大学 树枝状聚合物组合物和其在坏死性小肠结肠炎和其它胃肠道病症治疗中的用途
JP6986758B2 (ja) 2016-02-08 2021-12-22 ザ・ジョンズ・ホプキンス・ユニバーシティー デンドリマー−生体接着性ポリマーヒドロゲルナノ接着剤およびその使用
US11918657B2 (en) * 2017-11-10 2024-03-05 The Johns Hopkins University Dendrimer delivery system and methods of use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540664A (ja) 2007-10-05 2010-12-24 ウェイン ステート ユニバーシティー 合成物の持続的な放出のためのデンドリマー
US20130165771A1 (en) 2011-12-17 2013-06-27 Ming Ni Use of fitc-dextran as dye for fundus angiography and methods thereof
WO2014109927A1 (en) 2013-01-11 2014-07-17 The Regents Of The University Of Michigan Synthesis and isolation of dendrimer based imaging systems
CN103804693A (zh) 2014-01-24 2014-05-21 中国科学院化学研究所 树枝状聚缩酮及其制备方法和应用
JP2017514347A (ja) 2014-03-21 2017-06-01 サン パテント トラスト Ｄ２ｄ通信におけるスケジューリング要求手順

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Raymond Iezzi et al.，Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration，Biomaterials ，2011年11月01日，vol.33，p.979-988
Uri Soiberman et al.，Subconjunctival injectable dendrimer-dexamethasone gel for the treatment of corneal inflammation，Biomaterials，2017年02月16日，vol.125，p.38-53
Wojciech G.Lesniak et al.，Biodistribution of Fluorescently Labeled PAMAM Dendrimers in Neonatal Rabbits: Effect of Neuroinflammation，molecular pharmaceutics，2013年10月11日，vol.10，p.4560-4571

Also Published As

Publication number Publication date
CN110913916A (zh) 2020-03-24
US11160881B2 (en) 2021-11-02
IL270169A (https=) 2019-12-31
CA3061630A1 (en) 2018-11-01
IL270169B1 (en) 2024-04-01
AU2018258654A1 (en) 2019-12-12
WO2018201007A3 (en) 2019-01-03
US20200179537A1 (en) 2020-06-11
JP2020520393A (ja) 2020-07-09
CA3061630C (en) 2021-12-07
AU2018258654B2 (en) 2022-01-06
EP3615086A4 (en) 2021-01-06
IL270169B2 (en) 2024-08-01
EP3615086A2 (en) 2020-03-04
WO2018201007A2 (en) 2018-11-01

Similar Documents

Publication Publication Date Title
US20230092699A1 (en) Dendrimer compositions and their use in treatment of diseases of the eye
Cheng et al. pH-responsive multifunctional theranostic rapamycin-loaded nanoparticles for imaging and treatment of acute ischemic stroke
Nguyen et al. Gold nanorod enhanced photoacoustic microscopy and optical coherence tomography of choroidal neovascularization
US10238756B2 (en) Lipid nanoparticles and uses thereof
US20100034749A1 (en) Use of a Cationic Collodal Preparation for the Diagnosis and Treatment of Ocular Diseases
JP2007536272A (ja) 近視の処置法
ES2848209T3 (es) Direccionamiento específico de célula mediante sistemas portadores nanoestructurados
JP7178108B2 (ja) 血管造影において使用するためのデンドリマー組成物
JP7759322B2 (ja) 眼に薬物送達するためのデンドリマー組成物および方法
CN107050020A (zh) 用于治疗和诊断致盲性眼病的方法
CN103285408A (zh) Fitc-葡聚糖在制备眼底血管造影剂方面的应用
Xin et al. Ophthalmic drops with nanoparticles derived from a natural product for treating age-related macular degeneration
US20100098637A1 (en) Dye-loaded nanoparticle
Li et al. Zebrafish: a visual model to evaluate the biofate of transferrin receptor-targeted 7peptide-decorated coumarin 6 micelles
Russell et al. Fluorescent tracers for in vivo imaging of lymphatic targets
Shi et al. Recent advances in interventional fluorescence imaging: Toward the precise visualization of transarterial mini-invasive delivery systems
US20210236652A1 (en) Nanoparticles for treatment of choroidal neovascularization and other indications
US20120115771A1 (en) Carrier
HK40026651A (en) Dendrimer compositions for use in angiography
Spanò et al. Enhancing thrombolysis safety in Post-Acute ischemic stroke with tissue plasminogen Activator-Associated microparticles
McLean et al. Targeted 8-arm PEG Nanosystems for Localization of Choroidal Neovascularization Macular Degeneration Model
Moreira Development of aptamer nanoparticles for treatment of retinal diseases
Neto Drug Encapsulation in Extracellular Vesicles for Age-Related Macular Degeneration Treatment
CN118490640A (zh) Rgd@lp-2-dg及其在制备血管新生病药物中的应用和制备方法
Le Development of Particle Platforms for Delivery of Angiogenic Reagents to Treat Peripheral Arterial Diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220316

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220318

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221021

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221107

R150 Certificate of patent or registration of utility model

Ref document number: 7178108

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250